Antibody Bank
(Kato's Lab; Tohoku University)
Kato' lab in Tohoku University Graduate School of Medicine
mAb list
ATRX/ CCR2/ CCR3/ CCR4/ CCR6/ CCR8/ CCR9/ CXCR6/ CD19/ CD20/ CD39/ CD44s/ CD44v/ CD133/ CD271/ DGK/ Dog/ EGFR/ EpCAM/ HER2/ HER3/ HER4/ HGF/ IDH/ KLRG1/ PD-L1/ PD-L2/ PODXL/ PDPN (animal)/ RdRP/ SARS-CoV-2 (N/S2/bispecific/humanized)/ Tag/ TERT/ TIGIT/ TROP2/ XCR1
＜Peptide tag system＞
| PA tag NZ-1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PA tag mAb （NZ-1; rat IgG2a） |
PAtag (GVAMPGAEDDVV；12 amino acid); trademark: No. 5671624; from AMED・PDIS project | Purification, IP, IHC, WB, FACS | PEP2014;
JCS2016 PS2019; AC2021 Sci2022; PSSJ; Wako |
○ |
in preparation
|
| anti-PA14 tag mAb （NZ-1；rat IgG2a, lambda） |
PA14 tag (EGGVAMPGAEDDVV); from AMED・SentanBio | Purification, IP, IHC, WB, FACS |
PA14 tag system hGH-fusion Fab |
○ | in preparation |
| anti-PA16 tag mAb （NZ-1；rat IgG2a, lambda） |
PA16 tag（GLEGGVAMPGAEDDVV）; from AMED・SentanBio | Purification, IP, IHC, WB, FACS | C44Mab5; PMab202; PMab210; PMab213; PMab219; PMab233 | ○ | in preparation |
| MAP tag PMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-MAP tag mAb （PMab-1；rat IgG2a, kappa）--> PAtag |
MAPtag (GDGMVPPGIEDK；12 amino acids); trademark: No. 5988384; from AMED・KakushinBio; press release | Purification, IP, IHC, WB, FACS | MAB2016 BBREP2018 JB2020 |
○ |
AA; abcam; Nov; Merck; BioLegend in preparation |
| anti-MAP16 tag mAb （PMab-1；rat IgG2a, kappa） |
MAP16 tag (PGTGDGMVPPGIEDKI；16 amino acids); from AMED・Tousa | Purification, IP, IHC, WB, FACS | PMab-235
PMab-44_goat |
○ | in preparation |
| RAP tag PMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-RAP tag mAb (PMab-2；mouse IgG1, kappa)--> PAtag |
RAP tag (DMVNPGLEDRIE; 12 amino acids); from AMED・KakushinBio | Purification, IP, IHC, WB, FACS | MAB2017 FPS2020 PP2021 |
○ |
AA;
abcam Merck; BioLegend |
| anti-RAP14 tag mAb（double tag） (PMab-2; LpMab-7) |
RAP14 tag（DMVNPGLEDRIEDL; 14 amino acids）; from AMED・Tousa | Purification, IP, IHC, WB, FACS | PMab44; PMab256; PDF; PMab253 | ○ | |
| anti-RAP16 tag mAb （PMab-2；mouse IgG1, kappa） |
RAP16 (GPGDDMVNPGLEDRIE; 16 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS | PMab-225_alpaca
PMab-225_epitope PMab-44_alpaca |
○ | |
| RIEDL tag LpMab-7 | Character | Application | Ref | Gene cloning | Company |
| anti-RIEDL tagmAb (LpMab-7；mouse IgG1, kappa)-->PAtag |
RIEDLtag (RIEDL; 5 amino acids): from AMED・SentanBio | Purification, IP, IHC, WB, FACS | RIEDL; PMab237 (1); PMab237 (2); C44-5; C44-46; E134; E51 | ○ | abcam |
| MBP tag TMab-2 | Character | Application | Ref | Gene cloning | Company |
| anti-MBP tag mAb （TMab-2；rat IgG2b, kappa） |
specific for maltose-binding protein | IHC, WB | PubMed
|
○ | |
| anti-MBP tag mAb （YM-2；rat IgG2b, kappa） |
specific for maltose-binding protein | IHC, WB | PubMed
|
○ | BioLegend |
| BAP tag PMab-44 | Character | Application | Ref | Gene cloning | Company |
| anti-BAP tagmAb (PMab-44；mouse IgG1, kappa)--> PAtag |
BAP tag（EKTTLGVEDYTTTPAA; 16 amino acids); from AMED・BINDS・SentanBio | Purification, IP, IHC, WB, FACS | PMab247 PMab241 |
○ | Zenogen |
| LP tag LpMab-17 | Character | Application | Ref | Gene cloning | Company |
| anti-LP tag mAb (LpMab-17；mouse IgG1, kappa)-->PAtag |
LPタグ(NSVTGIRIEDLPTSES; 16 amino acids); from AMED・BINDS・SentanBio | Purification, IP, IHC, WB, FACS | PMab52 PMab231 |
○ |
BD Merck |
| His tag HisMab-1 | Character | Application | Ref | Gene cloning | Company |
| anti-His tag (HisMab-1;mouse IgG2b, kappa)-->PAtag | His tag (HHHH; 4 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS |
C20Mab60 Rituximab C20Mab11 |
○ | |
| anti-His tag; (HisMab-1-hG1；human IgG1, kappa) | His tag (HHHH; 4 amino acids); from AMED・SentanBio | Purification, IP, IHC, WB, FACS | ○ |
＜Chemokine receptor＞
| mouse CCR1 （CD191） | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-mouse CCR1 mAb | in preparation |
FACS | |||
| mouse CCR2 （CD192） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR2 mAb（C2Mab-6；rat IgG1, kappa） | specific for mouse CCR2; expressed in L1210; peptide immunization --> anti-human CCR2 |
FACS, WB, ICC |
C2Mab-6 epitope |
○ | in preparation |
| mouse CCR3 （CD193） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR3 mAb（C3Mab-2；rat IgG2b, kappa） |
specific formouse CCR3; expressed in P388 or J774-1; established by CBIS method | FACS |
C3Mab-2 ICC |
○ | |
| anti-mouse CCR3 mAb（C3Mab-3；rat IgG2a, kappa） | specifc mouse CCR3; expressed in P388 or J774-1; established by CBIS method。 | FACS |
C3Mab-3 epitope |
○ | |
| anti-mouse CCR3 mAb（C3Mab-4；rat IgG2a, kappa） | specific mouse CCR3; expressed in P388 or J774-1; established by CBIS method | FACS | epitope | ○ | in preparation |
| anti-mouse CCR3 mAb（C3Mab-6；rat IgG1, kappa） | specific mouse CCR3; expressed in P388 or J774-1; peptide immunization | FACS |
C3Mab-6 epitope |
○ | in preparation |
| anti-mouse CCR3 mAb（C3Mab-7；rat IgG1, kappa） | specific mouse CCR3; expressed in P388 or J774-1; peptide immunization | FACS |
C3Mab-7 epitope-1 epitope-2 |
○ | in preparation |
| mouse CCR4 （CD194） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR4 mAb（C4Mab-1；rat IgG1, kappa） | specific for mouse CCR4; expressed in P388 or J774-1; peptide immunization | FACS |
C4Mab-1 epitope |
○ | |
| mouse CCR5 （CD195） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR5 mAb | in preparation |
FACS | |||
| mouse CCR6 （CD196） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR6 mAb（C6Mab-9；rat IgG1, kappa） | specific for mouse CCR6; expressed in P388 or J774-1; peptide immunization
--> anti-human CCR6 |
FACS | ○ | in preparation | |
| anti-mouse CCR6 mAb（C6Mab-13；rat IgG1, kappa） | specific for mouse CCR6; expressed in P388 or J774-1; peptide immunization | FACS |
C6Mab-13 epitope |
○ | |
| mouse CCR7 （CD197） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR7 mAb | in preparation |
FACS | |||
| mouse CCR8 （CD198） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR8 mAb（C8Mab-1； rat IgG2a, kappa） |
specific mouse CCR8; expressed in P388, J774-1; established by CBIS method | FACS, ICC | C8Mab-1 | ○ | |
| anti-mouse CCR8 mAb（C8Mab-2； rat IgG2b, kappa） |
specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC （anti-CCR8 mAb of Shionogi） |
C8Mab-2 ICC |
○ | |
| anti-mouse CCR8 mAb（C8Mab-3； rat IgG1, kappa） |
specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC | C8Mab-3 | ○ | |
| mouse CCR8 (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR8 mAb (C8Mab-2-mG2a) | specific mouse CCR8; expressed in P388 or J774-1; established by CBIS method | FACS, ICC | ○ |
|
|
| mouse CCR9 （CD199） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR9 mAb（C9Mab-24；rat IgG2a, kappa） | specific for mouse CCR9; expressed in P388 or J774-1; peptide immunization --> anti-human CCR9 |
FACS、WB |
C9Mab-24 epitope |
○ | |
| mouse CCR10 | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR10 mAb | in preparation |
FACS | |||
| mouse CCR11 | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CCR11 mAb | in preparation |
FACS | |||
| mouse CXCR1 （CD181） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR1 mAb | in preparation |
FACS | |||
| mouse CXCR2 （CD182） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR2 mAb | in preparation |
FACS | |||
| mouse CXCR3 （CD183） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR3 mAb | in preparation |
FACS | |||
| mouse CXCR4 （CD184） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR4 mAb | in preparation |
FACS | |||
| mouse CXCR5 （CD185） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR5 mAb | in preparation |
FACS | |||
| mouse CXCR6 （CD186） | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR6 mAb(CX6Mab-1; rat IgG1, kappa) | specific for mouse CXCR6; expressed in P388 or J774-1; peptide immunization | FACS, WB |
CX6Mab-1 epitope-1 epitope-2 |
○ | in preparation |
| anti-mouse CXCR6 mAb(CX6Mab-5; rat IgG1, kappa) | specific for mouse CXCR6; expressed in P388 or J774-1; peptide immunization | FACS, WB | ○ | in preparation | |
| mouse CXCR7 (CD187) | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CXCR7 mAb | in preparation |
FACS | |||
| mouse XCR1 | Character | Application | Ref | Gene cloning | Company |
| anti-mXCR1 mAb | in preparation | FACS | |||
| mouse CX3CR1 | Character | Application | Ref | Gene cloning | Company |
| anti-mouse CX3CR1 mAb | in preparation |
FACS |
| human CCR2 （CD192） | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hCCR2 mAb (C2Mab-9；mouse IgG1, kappa) |
specific for human CCR2; expressed in U937 or NK cell; peptide immunization --> anti-mouse CCR2 |
FACS, ICC |
C2Mab-9 epitope |
○ | |
| human CCR6 （CD196） | Character | Application | Ref | Gene cloning | Company |
| anti-hCCR6 mAb (C6Mab-19；mouse IgG1, kappa) | specific for human CCR6; expressed in HepG2 or HuH-7; peptide immunization --> anti-mouse CCR6 |
FACS, IHC, ELISA |
MAB (submit) |
||
| human CCR9 （CD199） | Character | Application | Ref | Gene cloning | Company |
| anti-hCCR9 mAb (C9Mab-1；mouse IgG1, kappa) | specific for human CCR9; developmed by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) (SunRock) --> anti-mouse CCR9 | FACS |
C9Mab-1;
epitope ICC |
○ |
BD;
exbio Novus Thermo |
| anti-hCCR9 mAb (C9Mab-6；mouse IgG1, kappa） | specific for human CCR9; established by CBIS method; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
| anti-hCCR9 mAb (C9Mab-8；mouse IgG3, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
| anti-hCCR9 mAb (C9Mab-9；mouse IgG3, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-10；mouse IgG3, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-11；mouse IgG2a, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS、WB |
C9Mab-11 epitope |
○ | |
| anti-hCCR9 mAb (C9Mab-12；mouse IgG1, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-13；mouse IgG2a, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
| anti-hCCR9 mAb (C9Mab-14；mouse IgG1, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-16；mouse IgG1, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
| anti-hCCR9 mAb (C9Mab-17；mouse IgG2b, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-18；mouse IgG3, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| anti-hCCR9 mAb (C9Mab-19；mouse IgG1, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | restricted | |
| anti-hCCR9 mAb (C9Mab-21；mouse IgG3, kappa） | specific for human CCR9; established by peptide immunization; expressed in MOLT-4 (acute T lymphoblastic leukemia) | FACS | ○ | ||
| human XCR1 | Character | Application | Ref | Gene cloning | Company |
| anti-hXCR1 mAb (X1Mab-4；mouse IgG1, kappa） | specific for human XCR1; established by peptide immunization | FACS | |||
| anti-hXCR1 mAb (X1Mab-47；mouse IgM, kappa） | specific for human XCR1; established by CBIS (immunization of MDA-MB-157/PA-hXCR1) | FACS |
＜EGFR/HER2/HER3/HER4＞
| mouse EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb; EMab-300 (rat IgG1, kappa） | specific for mouse EGFR | FACS | EMab-300 | in preparation | |
| anti-mouse/human EGFR mAb; EMab-88 (mouse IgG1, kappa） | specific for EGFR; EMab-88 was developed against human EGFR; crossreacts with mouse EGFR (domain-III) | FACS | data | ○ |
| human EGFR domain-I | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb （EMab-23；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-I | FACS | ○ | ||
| anti-EGFR mAb （EMab-78；mouse IgG2b, kappa） |
specific for EGFR; reacts with domain-I | FACS | ○ | ||
| anti-EGFR mAb （EMab-129；mouse IgG1, lambda） |
specific for EGFR; reacts with domain-I | FACS | ○ | ||
| human EGFR domain-II | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb （EMab-19；mouse IgG2a, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | ○ | ||
| anti-EGFR mAb （EMab-33；mouse IgG1, kappa） |
specific for EGFR; reacts with domain-II | FACS | ○ | ||
| anti-EGFR mAb （EMab-57；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-II | FACS | ○ | ||
| anti-EGFR mAb （EMab-76；mouse IgG1, kappa） |
specific for EGFR; reacts with domain-II | FACS | ○ | ||
| human EGFR domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb （EMab-134；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-134
epitope-1 epitope-2 |
○ |
abcam BD |
| anti-EGFR mAb （EMab-51；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC | EMab-51 epitope |
○ | |
| anti-EGFR mAb （EMab-17；mouse IgG2a, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | EMab-17 metastasis |
○ | |
| anti-EGFR mAb （EMab-1；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
| anti-EGFR mAb （EMab-32；mouse IgG2a, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
| anti-EGFR mAb （EMab-114；mouse IgG2b, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
| anti-EGFR mAb （EMab-125；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | ○ | ||
| anti-EGFR mAb （EMab-139；mouse IgG1, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB | ○ | ||
| anti-EGFR mAb （EMab-151；mouse IgG2b, kappa） |
specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS | ○ | ||
| human EGFR domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb （EMab-95；mouse IgG1, kappa） |
specific for EGFR; reacts with domain-IV | FACS | ○ | ||
| anti-EGFR mAb （EMab-110；mouse IgG1, kappa） |
specific for EGFR; reacts with domain-IV | FACS | ○ |
| human EGFR (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb （134-mG2a；mouse IgG2a, kappa） |
mouse IgG2a version of EMab-134; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC/CDC, antitumor activities | 134-mG2a | ○ | |
| anti-EGFR mAb （51-mG2a；mouse IgG2a, kappa） |
mouse IgG2a version of EMab-51specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ | ||
| anti-EGFR mAb （51-mG2a-f；mouse IgG2a, kappa） |
core fucose-deficient mouse IgG2a version of EMab-51; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ | ||
| anti-EGFR mAb （recEMab-17-f；mouse IgG2a） |
core fucose-deficient mouse IgG2a version of EMab-17; specific for EGFR; crossreacts with dog EGFR; reacts with domain-III | FACS, ADCC/CDC, antitumor activities | ○ |
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EGFR mAb （134-mG2a-f；mouse IgG2a） |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR OS; Fibro Mammary |
○ | |
| anti-EGFR mAb （E134Bf；canine IgGB, kappa） |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
○ |
| bispecific | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog EGFR-dog HER2 mAb （E134B-H77scFv-f） |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | ○ | |
| anti-EGFR-PDPN mAb （E134-NZ1scFv-mG2a-f） |
bispecific mAb for EGFR and PDPN | FACS, WB, IHC, ADCC, CDC, antitumor activities | ○ |
| mouse HER2 （CD340） | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-300 ；rat IgG2b, kappa） |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | data
in preparation |
ongoing | |
| anti-HER2 mAb （H2Mab-303 ；rat IgG2a, kappa） |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | ongoing | in preparation | |
| anti-HER2 mAb （H2Mab-304 ；rat IgG1, kappa） |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | data
in preparation |
ongoing | in preparation |
| anti-HER2 mAb （H2Mab-307 ；rat IgG2a, kappa） |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS | ongoing | in preparation | |
| anti-HER2 mAb （H2Mab-314 ；rat IgG1, kappa） |
specific for mouse HER2
does not cross-react with dog HER2 |
FACS, WB | ongoing |
| mouse HER2 （CD340) mouse IgG2a | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-1301 ；rat IgG2a, lambda） |
Mab30; specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1316 ；rat IgG2a, kappa） |
Mab-31; specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1319 ；rat IgG2a, kappa） |
Mab-32; specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
| mouse HER2 （CD340) mouse IgG2a | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-1301-mG2a ；mouse IgG2a, kappa） |
specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1316-mG2a ；mouse IgG2a, kappa） |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1319-mG2a ；mouse IgG2a, kappa） |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
| mouse HER2 （CD340) humanized | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-1301-hG1 ；human IgG1, kappa） |
specific for mouse HER2;
cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1316-hG1 ；human IgG1, kappa） |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted | |
| anti-HER2 mAb （H2Mab-1319-hG1 ；human IgG1, kappa） |
specific for mouse HER2; cross-react with HER2 (human) does not cross-react with dog HER2 |
FACS | ongoing | restricted |
| HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-77；mouse IgG1, kappa） |
specific for HER2; crossreacts with dog HER2; (参考：TNBC) | FACS, WB, IHC | H2Mab-77 | ○ | BioLegnd |
| anti-HER2 mAb （H2Mab-119；mouse IgG1, kappa） |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-119 PCT/JP2021/043538 |
○ | |
| anti-HER2 mAb （H2Mab-139；mouse IgG1, kappa） |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | H2Mab-139 | ○ | abcam |
| HER2 domain-III | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb （H2Mab-19；mouse IgG2b, kappa） |
specific for HER2; crossreacts with dog HER2; domain-III | FACS, ADCC/CDC, antitumor activities | PC
CRC GBM |
○ | |
| anti-HER2 mAb （H2Mab-181；mouse IgG1, kappa） |
specific for HER2; crossreacts with dog HER2; domain-III; epitope: p373ー392。 | FACS, WB, IHC | H2Mab-181 epitope |
○ | |
| HER2 domain-IV | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb （H2Mab-41；mouse IgG2b, kappa） |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
○ | |
| anti-HER2 mAb (H2CasMab-1；mouse IgG1, kappa) |
specific for HER2; domain-IV | FACS, WB, IHC | ○ | restricted |
| HER2 (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H2Mab-77-mG2a-f；mouse IgG2a） |
specific for HER2; crossreacts with dog HER2; (ref：TNBC) | FACS, WB, IHC | ○ | ||
| anti-HER2 mAb （H2Mab-119-mG2a-f；mouse IgG2a） |
specific for HER2; crossreacts with dog HER2 | FACS, WB, IHC | ○ | ||
| anti-HER2 mAb （H2CasMab-1-mG2a-f；mouse IgG2a） |
specific for HER2; domain-IV | FACS, WB, IHC | ○ | restricted |
| dog HER2 domain-I | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER2 mAb （H77Bf；canine IgGB, kappa） |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
○ |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb （H3Mab-17；mouse IgG2a, kappa） |
specific for HER3 | FACS, ADCC/CDC, antitumor activities | H3Mab-17 | ○ | exbio |
| HER3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti HER3 mAb （H3Mab-1059；mouse IgG1,kappa） |
Mab1 for HER3 | FACS | restricted | ||
| anti HER3 mAb （H3Mab-1170；mouse IgG1,kappa） |
Mab2 for HER3 | FACS | restricted |
| HER4 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HER4 mAb (H4Mab-12~; mouse IgG) | specific for HER4 | FACS |
＜Immune checkpoint＞
| KLRG1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-KLRG1 mAb （KLMab-1；mouse IgG1, kappa） |
specific for human KLRG1 | FACS、ICC | KLMab-1 ICC |
○ |
| PD-L1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb （L1Mab-13；mouse IgG1, kappa） |
specific for human PD-L1 | FACS, WB, IHC (cell), IHC (tissue), ELISA | L1Mab-13 | ○ |
| PD-L1 (to IgG1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L1 mAb （13-mG2a-f；mouse IgG2a, kappa） |
specific for human PD-L1; core fucose-deficient IgG2a of L1Mab-13 | FACS, WB, IHC (cell), IHC (tissue), ELISA, ADCC/CDC, antitumor activities | 13-mG2a-f | ○ |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog PD-L1 mAb （L1Mab-347；mouse IgG1, kappa） |
specific for dog PD-L1 (extracellular domain) | FACS, IHC | ○ | ||
| anti-dog PD-L1 mAb （L1Mab-348； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-349； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-350； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-351； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-352； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
| anti-dog PD-L1 mAb （L1Mab-353； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-354； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
| anti-dog PD-L1 mAb （L1Mab-355； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-356； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA |
| PD-L2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PD-L2 mAb （L2Mab-1；mouse IgG2b, kappa） |
specific for PD-L2 | FACS, WB, IHC (cell) | ○ |
| TIGIT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TIGIT mAb （TgMab-2；mouse IgG1, kappa） |
specific for TIGIT | FACS、WB、ICC |
TgMab-2 ICC |
○ | BD |
＜Monoclonal antibodies for the other membrane proteins＞
| CD19 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb （C19Mab-1；mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | C19Mab-1 | ○ | |
| anti-CD19 mAb （C19Mab-2；mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | ||
| anti-CD19 mAb （C19Mab-3；mouse IgG1, kappa） |
specific for CD19; CBIS method; ectodomain of CD19 immunization | IHC,WB | C19Mab-3 | ○ | |
| anti-CD19 mAb （C19Mab-9G6； mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | restricted | |
| anti-CD19 mAb （C19Mab-10G3； mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ○ | restricted |
| CD19 (for CAR-T) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb （C19Mab-9G6-scFv；mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ○ | restricted | |
| anti-CD19 mAb （C19Mab-10G3-scFv；mouse IgG1, kappa） |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ○ | restricted |
| CD19 (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb （humC19Mab-9G6-hG1； human IgG1） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ongoing | restricted | |
| anti-CD19 mAb （humC19Mab-10G3-hG1； human IgG1） |
specific for CD19; CBIS method; LN229/CD19 immunization | FACS | ongoing | restricted |
| CD19 (humanized; for CAR-T) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD19 mAb （humC19Mab-9G6-scFv； human IgG1） |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ongoing | restricted | |
| anti-CD19 mAb （humC19Mab-10G3-scFv； human IgG1） |
specific for CD19; CBIS method; LN229/CD19 immunization | CART | ongoing | restricted |
| CD20 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| 抗CD20 mAb （C20Mab-11；mouse IgM, kappa） |
specific for CD20 | FACS, WB, IHC |
C20Mab-11 epitope |
ongoing | |
| 抗CD20 mAb （C20Mab-60；mouse IgG2a, kappa） |
specific for CD20; ref：rituximab | FACS, WB, IHC |
C20Mab-60 epitope-1 epitope-2 |
ongoing | BioLegnd |
| CD39 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD39 mAb （C39Mab-1；rat IgG2a, kappa） |
specific for mouse CD39 | FACS, WB | C39Mab-1 | ○ | in preparation |
| anti-CD39 mAb （C39Mab-2；rat IgG2a, lambda） |
specific for mouse CD39 | FACS | C39Mab-2 | ○ | in preparation |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb （C44Mab-5； mouse IgG1, kappa） |
Specific for CD44s (CD44 standard) | IHC, FACS, WB | C44Mab-5 epitope |
○ | abcam BioLegnd |
| anti-CD44s mAb （C44Mab-46； mouse IgG1, kappa） |
specific for CD44s (CD44 standard) | FACS, IHC, WB | C44Mab-46 epitope-1 epitope-2 |
○ |
| CD44s (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb （5-mG2a； mouse IgG2a） |
mouse IgG2a version of C44Mab-5; specific for CD44s (CD44 standard)。 | IHC, FACS, ADCC, CDC, antitumor activities | 5-mG2a | ○ |
| CD44s (mouse IgG2a-f) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb (C44Mab-46-mG2a-f；mouse IgG2a) |
mouse IgG2a version of C44Mab-46 specific for CD44s (CD44 standard) |
IHC, FACS, WB, ADCC, CDC, antitumor activities | ○ |
| CD44s | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44s mAb （C44Mab-1012； mouse IgM, kappa） |
Mab1 for CD44s (exon-6) | FACS | ○ | restricted | |
| anti-CD44s mAb （C44Mab-1075； mouse IgG2a, kappa） |
Mab2 for CD44s (exon-6) | FACS | ○ | restricted | |
| anti-CD44s mAb （C44Mab-1095； mouse IgG1, kappa） |
Mab3 for CD44s (exon-6) | FACS | restricted |
| CD44v3 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb （C44Mab-6； mouse IgG1, kappa） |
specific for CD44v3 (oral cancer and colon cancer) |
FACS, WB, IHC, ELISA | IJMS | ○ | in preparation |
| CD44v4 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v4 mAb （C44Mab-108； mouse IgG1, kappa） |
specific for CD44v4 (oral cancer) |
WB, IHC, ELISA | CIMB |
○ | in preparation |
| CD44v5 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v5 mAb （C44Mab-3； mouse IgG1, kappa） |
specific for CD44v5 (pancreatic cancer) |
FACS, WB, IHC, ELISA | antibodies | ○ | in preparation |
| CD44v6 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v6 mAb （C44Mab-9； mouse IgG1, kappa） |
specific for CD44v6 (colon cancer) |
FACS, WB, IHC, ELISA | IJMS | ○ | in preparation |
| CD44v7 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v7/v8 mAb （C44Mab-34； mouse IgG1, kappa） |
specific for CD44v7/v8 (oral cancer) |
FACS, WB, IHC, ELISA | Biomedicines | ○ | |
| CD44v8 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v8 mAb （C44Mab-94； mouse IgG1, kappa） |
specific for CD44v8 (gastric cancer) |
FACS, WB, IHC, ELISA | antibodies (submit) |
○ | |
| CD44v9 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v9 mAb （C44Mab-1； mouse IgG1, kappa） |
specific for CD44v9 (colon cancer) |
FACS, WB, IHC, ELISA | CIMB | ○ | |
| CD44v10 | Character | Application | Ref | Gene cloning | Company |
| anti-CD44v10 mAb （C44Mab-18； mouse IgM, kappa） |
specific for CD44v10 (oral cancer) |
FACS, WB, IHC, ELISA | CIMB (submit) |
○ |
| CD44v (mouse IgG1) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v10 mAb （C44Mab-18-mG1； mouse IgG1, kappa） |
specific for CD44v10 | FACS, WB, IHC, ELISA | ongoing | ○ |
| CD44v (mouse IgG2a-f) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb （C44Mab-6-mG2a-f；mouse IgG2a） |
IgG2a version of C44Mab-6 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v4 mAb (C44Mab-108-mG2a-f；mouse IgG2a) |
IgG2a version of C44Mab-108 | FACS, WB, IHC, ELISA | ongoing |
ongoing | |
| anti-CD44v5 mAb （C44Mab-3-mG2a-f；mouse IgG2a） |
IgG2a version of C44Mab-3 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v6 mAb （C44Mab-9-mG2a-f；mouse IgG2a） |
IgG2a version of C44Mab-9 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v7/v8 mAb （C44Mab-34-mG2a-f；mouse IgG2a） |
mouse IgG2a version of C44Mab-34 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v8 mAb （C44Mab-94-mG2a-f；mouse IgG2a） |
mouse IgG2a version of C44Mab-94 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v9 mAb （C44Mab-1-mG2a-f；mouse IgG2a） |
mouse IgG2a version of C44Mab-1 | FACS, WB, IHC, ELISA | ongoing | ongoing | |
| anti-CD44v10 mAb （C44Mab-18-mG2a-f；mouse IgG2a） |
mouse IgG2a version of C44Mab-18 | FACS, WB, IHC, ELISA | ongoing | ongoing |
| CD44v | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD44v3 mAb （C44Mab-1080； mouse IgG1, kappa） |
Mab6 for CD44v3 | FACS | restricted | ||
| anti-CD44v3 mAb （C44Mab-1006； mouse IgG1, kappa） |
Mab11 for CD44v3 | FACS | ○ | restricted | |
| anti-CD44v5 mAb （C44Mab-1088； mouse IgG1, kappa） |
Mab8 for CD44v5 | FACS | restricted | ||
| anti-CD44v5 mAb （C44Mab-1003； mouse IgG1, kappa） |
Mab12 for CD44v5 | FACS | ○ | restricted | |
| anti-CD44v6 mAb （C44Mab-1081； mouse IgG1, kappa） |
Mab7 for CD44v6 | FACS | restricted | ||
| anti-CD44v6 mAb （C44Mab-1089； mouse IgG1, kappa） |
Mab9 for CD44v6 | FACS | restricted | ||
| anti-CD44v6 mAb （C44Mab-1009； mouse IgG1, kappa） |
Mab13 for CD44v6 | FACS | ○ | restricted | |
| anti-CD44v7 mAb （C44Mab-1030； mouse IgM, kappa） |
Mab4 for CD44v7 | FACS | restricted | ||
| anti-CD44v7 mAb （C44Mab-1048； mouse IgG1, kappa） |
Mab5 for CD44v7 | FACS | restricted | ||
| anti-CD44v7 mAb （C44Mab-1034； mouse IgG1, kappa） |
Mab10 for CD44v7 | FACS | ○ | restricted |
| CD133 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD133 mAb （CMab-43；mouse IgG2a, kappa） |
specific for CD133 | FACS, WB, IHC, ADCC/CDC, antitumor activities | CMab-43 in vivo |
○ |
abcam BD |
| CD271 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD271抗体 （G4B1；mouse IgG2a, kappa） |
cancer-specific mAb for CD271 | FACS, WB, IHC | anti-CD271 mAb | ○ | in preparation |
| CD276 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-CD276 mAb | specific for CD276 |
| EpCAM (CD326) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb （EpMab-16；mouse IgG2a, kappa） |
specific for EpCAM | FACS, WB, IHC | EpMab-16 (1)
EpMab-16 (2) |
○ | merck |
| anti-EpCAM mAb （EpMab-37；mouse IgG1, kappa） |
specific for EpCAM | FACS, WB, IHC | EpMab-37 epitope |
○ | |
| anti-EpCAM mAb （EpMab-3；mouse IgG1, kappa） |
specific for EpCAM | FACS | ○ |
| EpCAM
(mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb （EpMab-37-mG2a-f；mouse IgG2a） |
specific for EpCAM | FACS, WB, IHC, ADCC, CDC, antitumor activities |
EpMab-37 (1) EpMab-37 (2) |
○ | in preparation |
| EpCAM | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-EpCAM mAb （EpMab-1123；mouse IgM, kappa） |
Mab1 for EpCAM | FACS | |||
| anti-EpCAM mAb （EpMab-1138；mouse IgM, kappa） |
Mab2 for EpCAM | FACS | |||
| anti-EpCAM mAb （EpMab-1147；mouse IgG1, kappa） |
Mab3 for EpCAM | FACS | ○ | restricted in preparation |
|
| anti-EpCAM mAb （EpMab-1007；mouse IgG1, kappa） |
Mab4 for EpCAM | FACS | ○ | restricted in preparation |
|
| anti-EpCAM mAb （EpMab-1013；mouse IgG1, kappa） |
Mab5 for EpCAM | FACS | ○ | restricted | |
| anti-EpCAM mAb （EpMab-1022；mouse IgG1, kappa） |
Mab6 for EpCAM | FACS | ○ | restricted | |
| anti-EpCAM mAb （EpMab-1069；mouse IgG1, kappa） |
Mab7 for EpCAM | FACS | ○ | restricted |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb （TrMab-6；mouse IgG2b, kappa） |
specific for human TROP2; (ref：TNBC) | IHC, WB, FACS |
TrMab-6 MCF7 TNBC |
○ |
exbio |
| anti-TROP2 mAb （TrMab-29；mouse IgG1, kappa） |
specific for human TROP2 | IHC, WB, FACS | TrMab-29 | ○ | merck |
| TROP2 (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb （Datopotamab；humanized IgG1, kappa） |
Humanized mAb for DS-1062/Dato-DXd (Daiichi-Sankyo) | FACS | ○ | ||
| anti-TROP2 mAb （Sacituzumab；humanized IgG1, kappa） |
Humanized mAb （Sacituzumab govitecan；Trodelvy） | FACS | ○ |
| TROP2 | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-TROP2 mAb （TrMab-1100；mouse IgG1, kappa） |
Mab1 for human TROP2 | FACS | ○ | restricted in preparation |
|
| anti-TROP2 mAb （TrMab-1148；mouse IgG1, kappa） |
Mab3 for human TROP2 | FACS | ○ | restricted in preparation |
|
| anti-TROP2 mAb （TrMab-1156；mouse IgG2b, kappa） |
Mab4 for human TROP2 | FACS | ○ | restricted in preparation |
| HGF | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-HGF mAb （t8E4；mouse IgG1, kappa） |
specific for active HGF | WB, IHC |
SREP IJMS |
○ | Merck |
| anti-HGF mAb （t5A11；mouse IgG1, kappa） |
specific for HGF | WB, IHC |
SREP IJMS |
○ | |
| anti-HGF mAb （t1E4；mouse IgG2b, kappa） |
specific for HGF | neutralization |
SREP |
○ |
| Podocalyxin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb （PcMab-47；mouse IgG1, kappa） |
specific for human PODXL | FACS, WB, IHC | PcMab-47 IHC_OSCC epitope |
○ | abcam exbio |
| anti-PODXL mAb （PcMab-6；mouse IgG1, kappa） |
anti-PODXL CasMab | FACS | patent | ○ | |
| anti-PODXL mAb （PcMab-60；mouse IgM, kappa） |
anti-PODXL CasMab | FACS | PcMab-60 epitope patent |
○ |
| Podocalyxin (mouse IgG2a) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb （47-mG2a；mouse IgG2a, kappa） |
IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a IHC_LK IHC_EC |
○ | |
| anti-PODXL mAb （47-mG2a-f；mouse IgG2a, kappa） |
core fucose-deficient IgG2a version of PcMab-47; specific for human PODXL | FACS, WB, IHC; ADCC/CDC, antitumor activities | 47-mG2a-f | ○ | |
| anti-PODXL mAb （PcMab-6-mG2a-f；mouse IgG2a） |
anti-PODXL CasMab; IgG2a version of PcMab-6 | FACS, ADCC・CDC | ○ | ||
| anti-PODXL mAb （60-mG2a；mouse IgG2a, kappa） |
anti-PODXL CasMab; IgG2a version of PcMab-60 | FACS, ADCC/CDC | 60-mG2a | ○ | |
| anti-PODXL mAb （60-mG2a-f；mouse IgG2a, kappa） |
anti-PODXL CasMab, core fucose-deficient IgG2a version of PcMab-60 | FACS, ADCC/CDC, antitumor activities | 60-mG2a-f | ○ |
| Podocalyxin (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-PODXL mAb （chPcMab-47；human IgG1） |
specific for human PODXL | FACS, WB, IHC | chPcMab-47 | ○ | |
| anti-PODXL mAb （humPcMab-6；human IgG1） |
CasMab for PODXL; humanized mAb originated from PcMab-6 | FACS | ○ |
| human podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hPDPN mAb（NZ-1; rat IgG2a） |
specific for human PDPN; the other clones: NZ-1.2( Sigma, Merck, MBL, Novus, Zenogen, Wako); NZ-1.3(Thermo), NC-08 （BioLegend） | IP、IHC, WB, FACS (Review; patent) |
NZ-1;
PIT NZ-1.2 CTC |
○ | Wako |
| anti-hPDPN mAb (LpMab-2；mouse IgG1, kappa) | CasMab | IHC, WB, FACS | Cells2022 LpMab-2 patent |
○ | |
| anti-hPDPN mAb (LpMab-3；mouse IgG1, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS | LpMab-3 epitope Structure |
○ | MCP |
| anti-hPDPN mAb (LpMab-7；mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | LpMab-7 OS epitope |
○ |
abcam MCP zenogen |
| anti-hPDPN mAb (LpMab-9；mouse IgG1, kappa) | specific for human PDPN; epitope: Thr25 | WB, FACS | LpMab-9 epitope |
○ | MCP |
| anti-hPDPN mAb (LpMab-10；mouse IgG3, kappa) | specific for human PDPN; epitope: PLAG1 Thr34 | IHC, WB, FACS | LpMab-10 | ○ | |
| anti-hPDPN mAb (LpMab-12；mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG3 Thr52 | IHC, WB, FACS | LpMab-12 | ○ |
CST
Merck Hycult MCP zenogen |
| anti-hPDPN mAb (LpMab-13；mouse IgG1, kappa) | specific for human PDPN; epitope: PLAG2-3 | IHC, WB, FACS | LpMab-13 | ○ | Merck Hycult |
| anti-hPDPN mAb (LpMab-16；mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS | patent 2018-123699 | ○ | |
| anti-hPDPN mAb (LpMab-17；mouse IgG1, kappa) | specific for human PDPN | IHC, WB, FACS press release |
LpMab-17 | ○ |
BD Merck Hycult |
| anti-hPDPN mAb (LpMab-19；mouse IgG2b, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC | LpMab-19 | ○ | Merck |
| anti-hPDPN mAb (LpMab-21；mouse IgG2a, kappa) | specific for human PDPN; epitope: Thr76 | IHC, WB, FACS, ADCC/CDC press release |
Cells2022 LpMab-21 in vivo |
○ |
Merck
BioLegend MCP |
| anti-hPDPN mAb (LpMab-23；mouse IgG1, kappa) | CasMab | IHC, WB, FACS | LpMab-23 IHC patent |
○ |
BD exbio zenogen |
| anti-hPDPN mAb (PMab-117；rat IgM, kappa) | CasMab | FACS | Cells2022 patent |
○ | zenogen |
| human podoplanin (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-human PDPN mAb（NZ-8; human IgG1） |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | NZ-8 | ○ | |
| anti-human PDPN mAb（NZ-12; human IgG1） |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | NZ-12 RIT |
○ | |
| anti-human PDPN mAb（NZ-16; human IgG1） |
specific for human PDPN; rat-human chimeric mAb originated from NZ-1 | IP、IHC, WB, FACS | RIT | ○ | |
| anti-human PDPN mAb（NZ-27; human IgG1） |
specific for human PDPN; humanized mAb originated from NZ-1 | IP、IHC, WB, FACS |
NZ-27 CAR-T |
○ | |
| anti-human PDPN mAb（chLpMab-2; human IgG1） |
CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-2 | IP、IHC, WB, FACS | chLpMab-2 | ○ | |
| anti-human PDPN mAb（chLpMab-7；human IgG1） | specific for human PDPN; mouse-human chimeric mAb originated from LpMab-7 | IHC, WB, FACS | chLpMab-7 | ○ | |
| anti-human PDPN mAb（chLpMab-23；human IgG1） | CasMab for human PDPN; mouse-human chimeric mAb originated from LpMab-23 | IHC, WB, FACS | chLpMab-23 | ○ | |
| anti-human PDPN mAb（humLpMab-23；human IgG1） | CasMab for human PDPN; humanized mAb originated from LpMab-23 | IHC, WB, FACS | ○ |
| mouse podoplanin | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti mouse PDPN mAb (PMab-1；rat IgG2a, kappa) |
specific for mouse PDPN --> anti-human PDPN |
IHC, WB, FACS | PMab-1 PMab-1_LEC epitope |
○ | abcam; MBL; Nov; Mer; BioL |
| anti mouse PDPN mAb (mPMab-1；mouse IgG2a) | specific for mouse PDPN | IHC, WB, FACS |
mPMab-1 |
○ | |
| rat PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-rat PDPN mAb （PMab-2；mouse IgG1, kappa） |
specific for rat PDPN | IHC, WB, FACS | PMab-2 PMab-2_epitope |
○ |
abcam Merck BioLegend |
| rabbit PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-rabbit PDPN mAb （PMab-32；mouse IgG1, kappa） |
specific for rabbit PDPN | IHC, WB, FACS | PMab-32 epitope |
||
| dog PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-dog PDPN mAb （PMab-38；mouse IgG1, kappa） |
specific for dog PDPN | IHC, WB, FACS | PMab-38;
SCC melanoma epitope |
○ |
zenogen Wako |
| anti-dog PDPN mAb （P38Bf；dog IgGB, kappa） |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
○ | |
| anti-dog PDPN mAb （PMab-48；mouse IgG1, kappa） |
specific for dog PDPN | IHC, WB, FACS | PMab-48 epitope |
○ | zenogen |
| bovine PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-bovPDPN mAb (PMab-44；mouse IgG1, kappa) | specific for bovine PDPN | IHC, WB, FACS | PMab-44;
epitope goat; sheep; alpaca |
○ | zenogen |
| cat PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-cat PDPN mAb （PMab-52；mouse IgM, kappa） |
specific for cat PDPN | IHC, WB, FACS | PMab-52;
epitope IHC-1; IHC-2 tiger PDPN |
○ | zenogen |
| tiger PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-tiger PDPN mAb （PMab-231；mouse IgG2a, kappa） |
specific for tiger PDPN | IHC, WB, FACS | PMab-231 epitope lion PDPN |
○ | zenogen |
| horse PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-horse PDPN mAb （PMab-219；mouse IgG2a, kappa） |
specific for horse PDPN | WB, FACS, IHC | PMab-219 epitope PMab-219_epitope |
○ | zenogen |
| anti-horse PDPN mAb （PMab-202；mouse IgG1, kappa） |
specific for horse PDPN | WB, FACS | PMab-202 epitope |
○ | zenogen |
| pig PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-pig PDPN mAb （PMab-213；mouse IgG2b, kappa） |
specific for pig PDPN | WB, FACS, IHC | PMab-213 epitope LEC |
○ | zenogen |
| anti-pig PDPN mAb （PMab-210；mouse IgG1, kappa） |
specific for pig PDPN | WB, FACS, IHC | PMab-210 epitope |
○ | zenogen |
| goat PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-goat PDPN mAb (PMab-235；mouse IgG1, kappa) | specific for goat PDPN | IHC, WB, FACS | PMab-235 epitope |
○ | zenogen |
| alpaca PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-aPDPN mAb (PMab-225；mouse IgG2b, kappa) | specific for alpaca PDPN | IHC, WB, FACS |
PMab-225 epitope |
○ | zenogen |
| Tasmanian devil PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-TasPDPN PDPN (PMab-233；mouse IgG1, kappa) | specific for Tasmanian devil PDPN | IHC, WB, FACS | PMab-233br> epitope | ○ | zenogen |
| bear PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-bear PDPN mAb （PMab-241；mouse IgG2b, kappa） |
specific for bear PDPN | IHC, WB, FACS | PMab-241 epitope |
||
| anti-bear PDPN mAb （PMab-247；mouse IgG1, kappa） |
specific for bear PDPN | IHC, WB, FACS | PMab-247 IHC epitope |
○ | zenogen |
| whale PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-whale PDPN mAb （PMab-237；mouse IgG1, kappa） |
specific for whale PDPN | IHC, WB, FACS | PMab-237 IHC epitope |
○ | zenogen |
| sheep PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-sheep PDPN mAb （PMab-256；mouse IgG1, kappa） |
specific for sheep PDPN | IHC, WB, FACS | PMab-256 epitope |
○ | zenogen |
| anti-sheep PDPN mAb （PMab-253；mouse IgM, kappa） |
specific for sheept PDPN | IHC, WB, FACS | PMab-253 | ○ | |
| anti-sheep PDPN mAb （PMab-260；mouse IgM, kappa） |
specific for sheep PDPN | IHC, WB, FACS | PMab-260 | ○ | |
| sea lion PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-seaPDPN mAb (PMab-269；mouse IgG1, kappa) | specific for sea lion PDPN | IHC, WB, FACS | PMab-269 epitope Steller Sea Lion |
○ | |
| elephant PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-elePDPN mAb (PMab-265；mouse IgM, kappa） | specific for elephant PDPN | FACS | PMab-265 | ||
| anti-elePDPN mAb (PMab-295；mouse IgG1, kappa） | specific for elephant PDPN | FACS, WB, IHC | PMab-295 epitope |
○ |
Ab.antibody |
| ferret PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-ferret PDPN mAb （PMab-241；mouse IgG2b, kappa） |
anti-bear PDPN mAb crossreacts with ferret PDPN | IHC, WB, FACS | PMab-241 | ||
| anti-ferret PDPN mAb （PMab-292；mouse IgG1, kappa） |
specific for ferret PDPN | IHC, WB, FACS | PMab-292 | ○ |
Ab.antibody |
| hamster PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-hamPDPN mAb (PMab-281；mouse IgG3, kappa) | specific for hamster PDPN | FACS, IHC | PMab-281
epitope |
○ | |
| anti-hamPDPN mAb (281-mG2a-f；mouse IgG2a, kappa) | specific for hamster PDPN; IgG2a version of PMab-281 | FACS, IHC |
PMab-281
epitope |
○ | |
| giraffe PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-girPDPN mAb (PMab-301；mouse IgG1, kappa) | specific for giraffe PDPN | FACS, WB, IHC | |||
| panda PDPN | Character | Application | Ref | Gene cloning | Company |
| anti-panPDPN mAb () | specific for panda PDPN |
＜細胞内タンパク質を標的とした抗体シリーズ＞
| ATRX | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-ATRX mAb （AMab-6；mouse IgG1, kappa） |
specific for human ATRX | IHC, WB | AMab-6 AMab-6_epitope AMab-6_IHC |
abcam |
| DGK | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-DGKalpha mAb （DaMab-2；mouse IgG1, kappa） |
specifi for DGKalpha | ICC | DaMab-2 epitope |
restricted | |
| anti-DGKalpha mAb （DaMab-8；mouse IgG1, kappa） |
specific for DGKalpha | IHC | DaMab-8 |
○ | restricted |
| anti-DGKgamma mAb （DgMab-6；mouse IgG1, kappa） |
specific for DGKgamma | ICC | DgMab-6 |
restricted | |
| anti-DGKzeta mAb （DzMab-1；rat IgG2b, kappa） |
specific for DGKzeta | ICC |
DzMab-1 epitope |
restricted | |
| anti-DGKeta mAb （DhMab-1；mouse IgG2a, kappa） |
specific for DGKeta | IHC | DhMab-1 | restricted | |
| anti-DGKeata mAb （DhMab-4；mouse IgG2b, kappa） |
specific for DGKeta | IHC |
DhMab-4 ICC |
restricted | |
| anti-DGKdelta mAb （DdMab-1；mouse IgG2a, kappa） |
specific for DGKdeta | IHC | DdMab-1 | restricted |
| IDH | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-IDH1-R132H mAb (HMab-1; mouse IgG1, kappa) | specific for IDH1-R132H | IHC, WB | HMab-1 | ○ |
Merck
MBL; IBL; Sigma |
| anti-IDH1-R132H mAb (HMab-2; mouse IgG1, kappa) | specific for IDH1-R132Hを | IHC, WB | HMab-2 | ○ | abcam |
| anti-IDH1-R132S mAb (SMab-1; mouse IgG1, kappa) | specific for IDH1-R132S | IHC, WB | SMab-1 | ○ |
abcam
IBL; MBL Merck_Sigma |
| anti-IDH1-R132G mAb (GMab-r1；rat IgG2a, kappa) | specific for IDH1-R132G | IHC, WB | GMab-r1 |
abcam MBL |
|
| anti-IDH2-R172K mAb (KMab-1；rat IgG2b, kappa) | specific for IDH2-R172K | IHC, WB | KMab-1 | abcam MBL |
|
| anti-IDH2-R172M mAb (MMab-1；rat IgG2b, kappa) | specific for IDH2-R172M | IHC, WB | MMab-1 |
abcam MBL |
|
| anti-IDH2-R172W mAb (WMab-1；rat IgG2b, kappa) | specific for IDH2-R172W | IHC, WB | WMab-1 |
abcam MBL |
|
| anti-IDH2-R172S mAb (SMab-2；mouse IgG1, kappa) | specific for IDH2-R172S | IHC, WB | SMab-2 | abcam | |
| anti-IDH1 mAb (RMab-3；mouse IgG1, kappa) | specific for IDH1 | IHC, WB | RMab-3 |
BD MBL |
|
| anti-IDH1 mAb (RcMab-1；rat IgG2a, kappa) | specific for IDH1 | IHC, WB | RcMab-1 |
abcam CST MBL |
|
| anti-IDH2 mAb (RMab-22；mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | RMab-22 | MBL | |
| anti-IDH2 mAb (KrMab-3；mouse IgG2b, kappa) | specific for IDH2 | IHC, WB | KrMab-3 | CST BioLegend MBL |
|
| anti-mIDH1/2 mAb (MsMab-1；mouse IgG1, kappa) | specific for mutated IDH1/2 | IHC, WB （IHCのref） |
TJEM Brain Tumor Pathol Cancer Med |
○ | abcam Merck |
| anti-mIDH1/2 mAb (MsMab-2；rat IgG2a, kappa) | specific for mutated IDH1/2 | IHC, WB | MsMab-2 | ○ | MBL |
| TERT | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-hTERT mAb （TpMab-1；mouse IgG1, kappa） |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-1 （press release） |
○ | |
| anti-hTERT mAb （TpMab-2；mouse IgG1, kappa） |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA | ○ | ||
| anti-hTERT mAb （TpMab-3；mouse IgG1, kappa） |
specific for phosphorylated threonine 249 of hTERT | IHC, WB, ELISA |
TpMab-3 （press release） |
○ | in preparation |
| anti-hTERT mAb （TwMab-1；mouse IgG1, kappa） |
specific for hTERT | IHC, WB, ELISA | TwMab-1 | ○ | in preparation |
| anti-hTERT mAb （TMab-6；mouse IgM, kappa） |
specific for hTERT | IHC |
TMab-6 TMab-6_epitope |
○ |
＜Monoclonal antibodies for SARS-CoV-2＞
| SARS-CoV-2 (S1 RBD) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-1；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 319-338aa。 RBD：Receptor binding domain |
ELISA,WB, IHC | ○ | ||
| anti- SARS-CoV-2 S1-RBD mAb （CvMab-2；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-3；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 469-478aa。 |
ELISA,WB, IHC, neutralization | |||
| anti SARS-CoV-2 S1-RBD mAb （CvMab-6；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC, neutralization | CvMab-6 | ○ | |
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-7；mouse IgM, kappa） |
specific for SARS-CoV-2 S1-RBD epitope:459-478aa。 |
ELISA, WB, IHC, neutralization | ○ | ||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-13；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC | ○ | ||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-17；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-18；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, neutralization, IHC | |||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-24；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, WB, IHC, neutralization | |||
| anti-SARS-CoV-2 S1-RBD mAb （CvMab-25；mouse IgG1, kappa） |
specific for SARS-CoV-2 S1-RBD epitope: 459-478aa。 |
ELISA, IHC, WB |
| SARS-CoV-2 (S1 N terminus) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb （CvMab-32；mouse IgG2b, kappa） |
specific for SARS-CoV-2 S1N terminus | ELISA, IHC, WB |
| SARS-CoV-2 (S2) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb （CvMab-36；mouse IgG1, kappa） |
specific for SARS-CoV-2 S2 | ELISA, WB | |||
| anti-SARS-CoV-2 mAb （CvMab-62；mouse IgG1, kappa） |
specific for SARS-CoV-2 S2 | ELISA | ○ |
| SARS-CoV-2 (bi-specific) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-SARS-CoV-2 mAb （CvMab-bis1） |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-H_CvM62scFv |
○ | |||
| anti-SARS-CoV-2 mAb （CvMab-bis2） |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-6-L_CvM62scFv |
○ | |||
| anti-SARS-CoV-2 mAb （CvMab-bis3） |
specific for SARS-CoV-2 S1+S2 bispecific mAb CvMab-62-H_CvM6scFv |
○ | |||
| anti-SARS-CoV-2 mAb （CvMab-bis4） |
specific for SARS-CoV-2 S1+S2
bispecific mAb CvMab-62-L_CvM6scFv |
○ |
| SARS-CoV-2 (humanized) | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| Bebtelovimab (human IgG1, lambda) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; weak activity for all variants | ○ | ||
| Cilgavimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Cilgavimab plus tixagevimab (EVUSHELD) |
Neutralization; weak activity for BA.2; resistant for BA.4/5 | ○ | ||
| Casirivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) Casirivimab plus imdevimab (Ronapreve) |
Neutralization; weak activity for Omicron | ○ | ||
| Bamlanivimab (human IgG1, kappa) |
specific for SARS-CoV-2 S1 (sequence) (Lancet) |
Neutralization; no activity for Omicron | ○ | ||
| Bebtelovimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | ○ | |||
| Cilgavimab-scFv (scFv-Fc of human IgG1) |
specific for SARS-CoV-2 S1 | ○ | |||
| CvMab-62-H_Bebtelovimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | ○ | |||
| CvMab-62-H_Cilgavimab-scFv (bispecific) |
specific for SARS-CoV-2 S1+S2 | ○ |
| RdRP | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-RdRP mAb （RdMab-2；mouse IgG2a, kappa） |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB, IP, ICC | RdMab-2 | ||
| anti-RdRP mAb （RdMab-13；mouse IgM, kappa） |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-13 | ||
| anti-RdRP mAb （RdMab-15；mouse IgG1, kappa） |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-15 | ||
| anti-RdRP mAb （RdMab-16；mouse IgG1, kappa） |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP ; Immunogen: RHTFSNYQHEETIYNLLKDC |
ELISA, WB | RdMab-16 | ||
| anti-RdRP mAb （RdMab-20；mouse IgG2b, kappa） |
specific for SARS-CoV-2 nsp12, catalytic subunit of the RdRP; Immunogen: TRALTAESHVDTDLTKPYIC; distinguishes nsp12 of SARS-CoV-2 from that of SARS-CoV |
ELISA, WB | RdMab-20 |
＜anti-dog protein monoclonal antibodies＞
| dog PDPN | Character | Application | Ref | Gene cloning | Company |
|---|---|---|---|---|---|
| anti-dog PDPN mAb （P38Bf；dog IgGB, kappa） |
core fucose-deficient type B of PMab-38 | IHC, WB, FACS |
P38Bf P38B_in vivo ADC |
○ | |
| dog EGFR | Character | Application | Ref | Gene cloning | Company |
| anti-EGFR mAb （134-mG2a-f；mouse IgG2a, kappa） |
core fucose-deficient mouse IgG2a version of EMab-134; reacts with domain-III | FACS, WB, IHC, ADCC, CDC, antitumor activities | CHO/dEGFR Osteosarcoma Fibroblastic Mammary |
○ | |
| anti-EGFR mAb （E134Bf；canine IgGB, kappa） |
core fucose-deficient canine IgGB version of EMab-134; specific for EGFR | FACS, WB, IHC, ADCC, CDC, antitumor activities | Mammary Fibro & Osteo |
○ | |
| dog HER2 | Character | Application | Ref | Gene cloning | Company |
| anti-HER2 mAb （H77Bf；canine IgGB, kappa） |
core fucose-deficient canine IgGB version of H2Mab-77 | FACS, WB, IHC, ADCC/CDC, antitumor activities | H77Bf OS fibro |
○ | |
| anti-HER2 mAb （H2Mab-41；mouse IgG2b, kappa） |
specific for HER2; crossreacts with dog HER2; domain-IV | FACS, antitumor activities | H2Mab-41
dogHER2 |
○ | |
| EGFR-HER2 (bispecific) | Character | Application | Ref | Gene cloning | Company |
| anti-dog EGFR-dog HER2 mAb （E134B-H77scFv-f） |
bispecific mAb for EGFR and HER2 | FACS, WB, IHC, ADCC, CDC, antitumor activities | E134B-H77scFv-f | ○ | |
| dog PD-L1 | Character | Application | Ref | Gene cloning | Company |
| anti-dog PD-L1 mAb （L1Mab-347；mouse IgG1, kappa） |
specific for dog PD-L1 | FACS, IHC | ○ | ||
| anti-dog PD-L1 mAb （L1Mab-348； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-349； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-350； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-351； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-352； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
| anti-dog PD-L1 mAb （L1Mab-353； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-354； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA, IHC | |||
| anti-dog PD-L1 mAb （L1Mab-355； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA | |||
| anti-dog PD-L1 mAb （L1Mab-356； mouse IgG1, kappa） |
specific for dog PD-L1 (intracellular domain) | ELISA |
本抗体バンクは、AMED創薬等支援技術基盤プラットフォーム（平成２４年度〜２８年度）およびAMED創薬ライフサイエンス研究支援基盤事業（平成２９年度〜３３年度）の成果です。ご希望の方は、下記にご連絡ください。
担当者連絡先：東北大学大学院医学系研究科 抗体創薬学分野 加藤 幸成
E-mail：yukinari.kato.e6（アット）tohoku.ac.jp
担当者連絡先：東北大学大学院医学系研究科 抗体創薬学分野 加藤 幸成
E-mail：yukinari.kato.e6（アット）tohoku.ac.jp
細胞バンクもご覧下さい。